MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Inefficient immune response is a major glitch during tumor growth and progression. Chaotic and leaky blood vessels created in the process of angiogenesis allow tumor cells to escape and extricate anti-cancer immunity. Proangiogenic characteristics of hypoxic tumor microenvironment maintained by low oxygen tension attract endothelial progenitor cells, drive expansion of cancer stem cells, and deviantly differentiate monocyte descendants. Such cellular milieu further boosts immune tolerance and eventually appoint immunity for cancer advantage. Blood vessel normalization strategies that equilibrate oxygen levels within tumor and fix abnormal vasculature bring exciting promises to future anticancer therapies especially when combined with conventional chemotherapy. Recently, a new group of microRNAs (miRs) engaged in angiogenesis, called angiomiRs and hypoxamiRs, emerged as new therapeutic targets in cancer. Some of those miRs were found to efficiently regulate cancer immunity and their dysregulation efficiently programs aberrant angiogenesis and cancer metastasis. The present review highlights new findings in the field of miRs proficiency to normalize aberrant angiogenesis and to restore anti-tumor immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626 · cited 2×
“For example, hematopoietic cells are characterized by the following miRs: miR-142, -144, -150, -155, and 223 (Landgraf et al. 2007).”
BackgroundSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · cited 2×
“Especially anti-VEGF monotherapies failed (Carmeliet and Jain 2011a; Cobleigh et al. 2003; Giantonio et al. 2007; Jain et al. 2006) since anti-VEGF/VEGFR treatments boost hypoxic state that further allow for selection of highly resistant and aggressive stem-like cancer cells with progressively lower response to conven…”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Requirement of bic/microRNA-155 for Normal Immune Function
Rodriguez, A., Vigorito, E., Clare, S., Warren, M. V., Couttet, P., Soond, D. R., van Dongen, S., Grocock, R. J., Das, P. P., Miska, E. A., et al. (2007) · Science · doi:10.1126/science.1139253 · Cited by 1,833 · cited 3×
“miR-155 plays a crucial role in development, maintenance, and function of immune system (Rodriguez et al. 2007).”
BackgroundNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · cited 1×
“It states that cautious use of anti-angiogenic therapy creates a ''normalization window'' that reverses aberrant angiogenesis, leads to normalized vascular phenotype, and reduces vessel permeability and hypoxia (Goel et al. 2011, 2012).”
BackgroundTili, E., Michaille, J.-J., Cimino, A., Costinean, S., Dumitru, C. D., Adair, B., Fabbri, M., Alder, H., Liu, C. G., Calin, G. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5082 · Cited by 1,304 · cited 3×
“…of human NK cell activation Okada et al. (2010) Association in the response to TLR ligands, PAMPs and role in differentiation of Th1 vs. Th2 T cells Tili et al. (2007) Regulation of the release of inflammatory mediators during the innate immune response Lu et al. (2009) O'Connell et al. (2009)…”
BackgroundRegulation of progenitor cell proliferation and granulocyte function by microRNA-223
Johnnidis, J. B., Harris, M. H., Wheeler, R. T., Stehling-Sun, S., Lam, M. H., Kirak, O., Brummelkamp, T. R., Fleming, M. D., & Camargo, F. D. (2008) · Nature · doi:10.1038/nature06607 · Cited by 1,208 · cited 3×
“…et al. 2005). miR-223 promotes differentiation of myeloid blast cells in bone marrow (Fazi et al. 2005) and regulates activation of granulocytes (Johnnidis et al. 2008). miR-222 and miR-339 are oncomiRs that directly influence tumor immune responses by suppression of intracellular cell adhesion…”
BackgroundTong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 1×
“Current aims of anti-angiogenic therapy is to create a normalization window where blood vessels regain their typical structure with decreased permeability for better drug penetration (Jain 2005; Tong et al. 2004; Wildiers et al. 2003).”
BackgroundA MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055 · cited 1×
“…(Chan et al. 2011) miR-31 (Liu et al. 2010) miR-378 (Fang et al. 2012) miR-107 (Yamakuchi et al. 2010) miR-449a/b (Muth et al. 2010) miR-130 (Kulshreshtha et al. 2007; Saito et al. 2011) miR-138 (Song et al. 2011) miR-199a (Mizuno et al. 2012) miR-519c (Cha et al. 2010) The miRs classifed…”
Sheedy, F. J., Palsson-McDermott, E., Hennessy, E. J., Martin, C., O'Leary, J. J., Ruan, Q., Johnson, D. S., Chen, Y., & O'Neill, L. A. J. (2010) · Nature Immunology · doi:10.1038/ni.1828 · Cited by 1,005
Fasanaro, P., D'Alessandra, Y., Di Stefano, V., Melchionna, R., Romani, S., Pompilio, G., Capogrossi, M. C., & Martelli, F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800731200 · Cited by 912
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
Boldin, M. P., Taganov, K. D., Rao, D. S., Yang, L., Zhao, J. L., Kalwani, M., Garcia-Flores, Y., Luong, M., Devrekanli, A., Xu, J., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101823 · Cited by 861
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 2×
“Additionally, VEGF was proven to possess additive effect on immunosuppression in tumor by attracting regulatory T cells (Tregs) and Gr1 ? myeloid suppressor cells (Li et al. 2006; Shojaei et al. 2007).”
BackgroundGenome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells
Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05563 · Cited by 835 · cited 1×
“A few Treg-specific miRs are directly regulated by Foxp3; one of them is miR-155 that is important in response of Tregs to IL-2 by targeting SOCS1 and as an oncogene is constitutively and abundantly expressed in Tregs (Lu and Rudensky 2009; Lu et al. 2009; Marson et al. 2007; Zheng et al. 2007).”
BackgroundInositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826
Hou, J., Wang, P., Lin, L., Liu, X., Ma, F., An, H., Wang, Z., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900707 · Cited by 739
Foxp3 occupancy and regulation of key target genes during T-cell stimulation
Marson, A., Kretschmer, K., Frampton, G. M., Jacobsen, E. S., Polansky, J. K., MacIsaac, K. D., Levine, S. S., Fraenkel, E., von Boehmer, H., & Young, R. A. (2007) · Nature · doi:10.1038/nature05478 · Cited by 724 · cited 1×
“A few Treg-specific miRs are directly regulated by Foxp3; one of them is miR-155 that is important in response of Tregs to IL-2 by targeting SOCS1 and as an oncogene is constitutively and abundantly expressed in Tregs (Lu and Rudensky 2009; Lu et al. 2009; Marson et al. 2007; Zheng et al. 2007).”
BackgroundRolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695 · cited 2×
“The histidine-rich glycoprotein can downregulate PlGF and induce blood vessel maturation, inhibition of hypoxia and switch from pro-tumorogenic M2 macrophages to M1 with anti-tumor activity (Huang et al. 2011b; Rolny et al. 2011).”
BackgroundO'Connell, R. M., Rao, D. S., Chaudhuri, A. A., Boldin, M. P., Taganov, K. D., Nicoll, J., Paquette, R. L., & Baltimore, D. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072108 · Cited by 681 · cited 2×
“155 in hematopietic cells leads in mice to malignancy, myeloproliferative disorder, and in human to acute myeloid leukemia (Costinean et al. 2006; O’Connell et al. 2008).”
BackgroundShrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Why are tumour blood vessels abnormal and why is it important to know?
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611 · cited 1×
“Tumor vessels are highly irregular; the junctions among endothelial cells and connective tissue cells such as perivascular cells are loose, leading to leaky vascular structure with multiple fenestrations (Fukumura et al. 2010; Nagy et al. 2009).”
BackgroundThe Kinase Akt1 Controls Macrophage Response to Lipopolysaccharide by Regulating MicroRNAs
Androulidaki, A., Iliopoulos, D., Arranz, A., Doxaki, C., Schworer, S., Zacharioudaki, V., Margioris, A. N., Tsichlis, P. N., & Tsatsanis, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.024 · Cited by 581 · cited 1×
“…Fazi et al. (2005), Johnnidis et al. (2008), Li et al. (2010), Muzio et al. (2000) Let-7 family TLR4, IL-6 Inhibition of inflammatory signaling Androulidaki et al. (2009), Asirvatham et al. (2009) TCR T cell receptor, ICAM-1 intracellular cell adhesion molecule-1, iNKT invariant NKT, Th1 T…”
BackgroundBazzoni, F., Rossato, M., Fabbri, M., Gaudiosi, D., Mirolo, M., Mori, L., Tamassia, N., Mantovani, A., Cassatella, M. A., & Locati, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810909106 · Cited by 548
MicroRNAs and immunity: Novel players in the regulation of normal immune function and inflammation
Sonkoly, E., Ståhle, M., & Pivarcsi, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.01.005 · Cited by 523 · cited 2×
“It is a constituent of innate response to a variety of inflammatory mediators (Sonkoly et al. 2008; Tili et al. 2007) and is essential for proper T cell responses. miR-155 as oncomiR directly links immunity with oncogenesis and is dependent on MAPK signaling (O'Connell et al. 2007).”
BackgroundMelder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., & Jain, R. K. (1996) · Nature Medicine · doi:10.1038/nm0996-992 · Cited by 451
MicroRNA regulation of DNA repair gene expression in hypoxic stress
Crosby, M. E., Kulshreshtha, R., Ivan, M., & Glazer, P. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2516 · Cited by 437 · cited 4×
“…miR-155 (Bruning et al. 2011) miR-130 (Saito et al. 2011) miR-17-5p miR-16 (Dejean et al. 2011; Hua et al. 2006) miR-210 (Chan and Loscalzo 2010; Crosby et al. 2009a, b; Fasanaro et al. 2008; Giannakakis et al. 2008) miR-145 (Bussolati et al. 2012; Xu et al. 2012) miR-18a miR-20a (Hua et al.…”
BackgroundInfluentialMicroRNA profiling of the murine hematopoietic system
Monticelli, S., Ansel, K. M., Xiao, C., Socci, N. D., Krichevsky, A. M., Thai, T.-H., Rajewsky, N., Marks, D. S., Sander, C., Rajewsky, K., et al. (2005) · Genome Biology · doi:10.1186/gb-2005-6-8-r71 · Cited by 436
Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7723 · Cited by 413 · cited 1×
“However, direct targeting of VEGF as addition to standard chemotherapy showed improvements in patient outcomes (Saltz et al. 2008; Tebbutt et al. 2010).”
BackgroundNF-κB dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies
Zhao, J. L., Rao, D. S., Boldin, M. P., Taganov, K. D., O'Connell, R. M., & Baltimore, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105398108 · Cited by 386 · cited 1×
“NF-jb dysregulation in miR-146a deficient mice drives the development of myeloid malignancies (Zhao et al. 2011).”
BackgroundVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352 · cited 2×
“Indirect inhibitors of angiogenesis target tumor cell oncogenes such as HER-2, the PI3K-AKT-mTOR axis, Ras and epidermal growth factor receptor, and include endocrine therapies and metronomic chemotherapy (Goel et al. 2012).”
BackgroundRegulation of angiogenesis and choroidal neovascularization by members of microRNA-23∼27∼24 clusters
Zhou, Q., Gallagher, R., Ufret-Vincenty, R., Li, X., Olson, E. N., & Wang, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105254108 · Cited by 341
Cardoso, A. L., Guedes, J. R., Pereira de Almeida, L., & Pedroso de Lima, M. C. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03514.x · Cited by 336 · cited 1×
“…et al. (2005), Xiao et al. (2007) miR-155 SOCS1, SHIP1, c-Maf, Pro-inflammatory role in microglia and in the progression of the immune response Cardoso et al. (2012) FADD, IKKe, Ripk1, c-Myb, Liu et al. (2012) Regulation of human NK cell activation Okada et al. (2010) Association in the…”
BackgroundThe effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311 · cited 1×
“In some studies VEGF has been shown to inhibit the maturation and function of dendritic cells (Gabrilovich et al. 1996; Osada et al. 2008).”
BackgroundRosa, A., Ballarino, M., Sorrentino, A., Sthandier, O., De Angelis, F. G., Marchioni, M., Masella, B., Guarini, A., Fatica, A., Peschle, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706963104 · Cited by 285 · cited 1×
“With collaboration of miR-155, -222 and -503, -424 regulates monocyte differentiation (Forrest et al. 2010; Rosa et al. 2007).”
BackgroundNoman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256 · cited 2×
“Hypoxic condition induces dedifferentiation of cells, epithelial-mesenchymal transition , increased cell migration and invasion, and high resistance to chemo-, radio-(Teicher 1996), and immunotherapy (Noman et al. 2011).”
BackgroundDifferential expression of microRNAs in hematopoietic cell lineages
Merkerova, M., Belickova, M., & Bruchova, H. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2008.01111.x · Cited by 240 · cited 3×
“Different immune cell types can express the same miRs; however, their magnitude of expression can be altered, for example miR342 is 10-times more abundant in T cells than B cells (Merkerova et al. 2008).”
BackgroundMolecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
MicroRNA-519c Suppresses Hypoxia-Inducible Factor-1α Expression and Tumor Angiogenesis
Cha, S.-T., Chen, P.-S., Johansson, G., Chu, C.-Y., Wang, M.-Y., Jeng, Y.-M., Yu, S.-L., Chen, J.-S., Chang, K.-J., Jee, S.-H., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2448 · Cited by 202
Thiel, M., Caldwell, C. C., Kreth, S., Kuboki, S., Chen, P., Smith, P., Ohta, A., Lentsch, A. B., Lukashev, D., & Sitkovsky, M. V. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000853 · Cited by 175
microRNA-221 regulates high glucose-induced endothelial dysfunction
Li, Y., Song, Y.-H., Li, F., Yang, T., Lu, Y. W., & Geng, Y.-J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.02.013 · Cited by 158 · cited 1×
“They specifically target stem cell factor receptor and c-kit and thus are able to inhibit angiogenesis by reducing endothelial cell migration and proliferation (Li et al. 2009; Matsui et al. 2004; Poliseno et al. 2006).”
BackgroundMicroRNA-101 targets MAPK phosphatase-1 to regulate the activation of MAPKs in macrophages
Zhu, Q.-Y., Liu, Q., Chen, J.-X., Lan, K., & Ge, B.-X. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000798 · Cited by 152
Carreau, A., Kieda, C., & Grillon, C. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.08.011 · Cited by 88 · cited 1×
“Nitric oxide has been shown to modulate endothelial interactions and expression of junction molecules such as CD31 (Carreau et al. 2011).”
BackgroundSelf-citation
Cited by
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis
Annese, T., Tamma, R., De Giorgis, M., & Ribatti, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581007 · Cited by 288
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00602-3 · Cited by 267
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Klimkiewicz, K., Weglarczyk, K., Collet, G., Paprocka, M., Guichard, A., Sarna, M., Jozkowicz, A., Dulak, J., Sarna, T., Grillon, C., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.006 · Cited by 70
“The angiogenesis-controlling MiRs, angiomiRs and hypoxamiRs, are induced by tumour hypoxia and often promote pathologic vasculature; thus they constitute therapeutic targets [22].”
BackgroundSelf-citation
Metadata
- Authors
- Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kieda, C.
- Venue
- Archivum Immunologiae et Therapiae Experimentalis
- Publisher
- Walter de Gruyter GmbH
- Published
- 2013-04-11
- Volume
- 61
- Issue
- 4
- Pages
- 285-299
- ISSN
- 0004-069X (ISSN-L)
- 1661-4917
- OpenAlex
- W2041884448
- Cited by
- 30
- References
- 44
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.